Showing 2491-2500 of 2727 results for "".
- SENTE Launches Collaborations with Galderma, The HydraFacial Companyhttps://modernaesthetics.com/news/sente-launches-collaborations-with-galderma-the-hydrafacial-company/2471981/New strategic collaborations are intended to broaden the reach of SENTÉ and further expand their disruptive professional grade skin care product portfolio, the company says. Both collaborations will offer consumers the opportunity
- Sinclair Pharma: Acquisition by Huadong Medicine Company Limited Now Completehttps://modernaesthetics.com/news/sinclair-pharma-acquisition-by-huadong-medicine-company-limited-now-complete/2471988/Huadong Medicine Company Limited (HMC) has acquired Sinclair Pharma Limited, a global aesthetics company headquartered in London, UK, in a deal worth approximately $222 million. HMC is a well-known Chinese pharmaceutical listed company that has established a leading aesthetics business in China a
- FDA Green Light's Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://modernaesthetics.com/news/fda-green-lights-galdermas-restylane-lyft-for-midface-injection-via-cannula/2471998/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the
- Steady Increase in Facial Asymmetry with Aginghttps://modernaesthetics.com/news/steady-increase-in-facial-asymmetry-with-aging/2472000/Facial asymmetry increases steadily with age – a finding with important implications for facial rejuvenation and reconstructive procedures, reports a study in the November issue of Plastic and Reconstructive Surgery. Three-dimensional digital imaging techniques show a subtle but sig
- Scott Peterson, PhD is Now Head of Medical Affairs at Evolushttps://modernaesthetics.com/news/scott-peterson-phd/2472004/R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aestheti
- Bellus Recognized with Multiple Aesthetic Awardshttps://modernaesthetics.com/news/bellus-recognized-with-multiple-aesthetic-awards/2472006/Bellus Medical topped the charts in eight categories presented by the 2018 Aesthetic Everything® Awards: · Top Aesthetic Companies · Top Skin Care Devices (SkinPen&r
- xMedica Launches Aesthetics Conference Focused on Energy Based Treatments for Male and Female Sexual Wellnesshttps://modernaesthetics.com/news/xmedica-launches-aesthetics-conference-focused-on-energy-based-treatments-for-male-and-female-sexual-wellness/2472007/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- ARTAS iX: Real-World Evaluation Study Shows Benefithttps://modernaesthetics.com/news/artas-ix-real-world-evaluation-study-shows-benefit/2472009/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study of The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implan
- New from Lumenis: SPLENDOR X Laser Hair Removal Solutionhttps://modernaesthetics.com/news/new-from-lumenis-splendor-x-laser-hair-removal-solution/2472011/Lumenis Ltd. has launched SPLENDOR X, the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology was showcased for the first time at the 2018 American Society of Dermatological Surgery (ASDS) in Phoenix thi
- Galderma Announces the Start of Six New Aesthetic Studieshttps://modernaesthetics.com/news/galderma-announces-the-start-of-six-new-aesthetic-studies/2472014/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and